UMB 425 is being called a breakthrough in the development of therapeutics to treat chronic pain, acts on two different opioid receptors with diminished tolerance over time and no obvious toxic effects.
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences (PSC) at the University of Maryland School of Pharmacy (UMSOP), has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain. Spotlighted in a recent issue of ACS Chemical Neuroscience, the compound, known as UMB 425, is as strong as morphine, but displays diminished tolerance over time with no obvious toxic effects.
“UMB 425 is a breakthrough in the development of therapeutics to treat chronic pain,” says Coop. “Unlike other drugs developed to act on only one biological target, UMB 425 acts on two different opioid receptors in the body. When activated at the same time, these receptors work together to provide pain relief and slow the body’s development of tolerance to the drug. This diminished tolerance allows a lower dose of the opioid to be administered for a longer time period, while still achieving the same level of pain relief.”
For individuals living with chronic pain, either as a result of injury or disease such as arthritis, opioids are the standard treatment. But as the dosage increases to offset the body’s tolerance to their effects, opioids cause a number of adverse effects, including constipation, nausea, drowsiness, and dizziness. The unique dual-profile of UMB 425 – made possible through Coop’s collaborations with Alexander MacKerell, PhD, professor in PSC and director of the School’s Computer Aided Drug Design Center, and Maureen Kane, PhD, assistant professor in PSC and co-director of the School’s Mass Spectrometry Facility – provides both pain relief as well as diminished tolerance in one drug.
“Historically, medicinal chemists have developed drugs aimed at only one biological target,” says Coop. “However, two drugs administered together have the potential to metabolize differently in different individuals, as well as affect patients’ adherence to both drugs. A single compound that is able to provide both pain relief and diminished tolerance has the advantage of a defined ratio that we can optimize to ensure patients receive the maximum pain relief, while experiencing minimum adverse effects.”
Coop and his team conducted several in vitro and in vivostudies to determine the drug’s effectiveness in alleviating pain and diminishing tolerance over time. If future research and clinical trials are successful, UMB 425 could have a significant impact on the treatment and quality of life for individuals living with chronic pain.
“The clinical implication of this research has the potential to be tremendous,” says Mary Lynn McPherson, PharmD, BCPS, CPE, professor and vice chair for academic affairs in the Department of Pharmacy Practice and Science, and an international authority in the fields of pain management and palliative care. “If clinicians can prescribe lower doses of opioids, they will not have to raise a patient’s dose because of tolerance to the analgesic effects. Using lower doses will result in less severe adverse effects for the patient, both short-term effects such as nausea and constipation, as well as long-term adverse effects on the endocrine and immunologic systems. This would be a highly significant advance in pain management.”
The Latest on: Chronic Pain
Opioids no better than common painkillers in chronic pain study
on March 16, 2018 at 9:19 pm
Doctors and patients have long assumed that opioids are uniquely powerful medicines for chronic pain, despite their risks. But it turns out that this reputation may be a myth. A government-funded study published this month is among the first long-term ... […]
A senior moment: Chronic pain: How does it hurt?
on March 16, 2018 at 4:03 pm
The last column chronicled one man’s search for therapies and medications to alleviate pain from a herniated spinal disc. Email responses from readers let me know that he was not alone. The Institute of Medicine estimates that 116 million adults ... […]
I tested a Casper mattress to help with my chronic back pain
on March 16, 2018 at 7:44 am
Creating the ideal sleeping environment is an involved process no matter what. But building the ideal bed takes an extra dose of consideration and research when you suffer from any form of chronic pain. When positioned incorrectly, the hours we spend ... […]
Israeli med-tech startup aims to end chronic back pain
on March 14, 2018 at 7:07 am
We recently caught up with ZygoFix CEO Ofer Levy to learn more about the idea behind the company’s miniature spine implant that achieves joint fusion — all without screws. How did the idea for your company develop? Be the first to know - Join our ... […]
No Strong Evidence Marijuana Relieves Chronic Nerve Pain, Study Finds
on March 13, 2018 at 10:03 am
There’s no good evidence that marijuana and cannabis-derived compounds help the nerve pain associated with chemotherapy or conditions like fibromyalgia—and side effects may mean the treatments do more harm than good. Nerves send all kinds of pain ... […]
Dealing with chronic pain? Try a cannabis suppository treatment
on March 13, 2018 at 4:05 am
More than 158.8 million people around the globe are using cannabis, according to the United Nations (U.N.). This is approximately 3.8 percent of the global population and the figure will undoubtedly grow as cannabis legalization spreads. First used for ... […]
Have scientists found an answer to chronic pain?
on March 13, 2018 at 12:04 am
Using computer modeling, researchers have designed a new compound that may help to treat neuropathic pain. In animal trials, it produced immediate, long-lasting therapeutic effects. Neuropathic pain is a chronic condition wherein people have a heightened ... […]
A new solution for chronic pain
on March 12, 2018 at 3:10 am
A molecule selected on the basis of data analysis and optimised via medicinal chemistry (BDT001) prevents the binding of FL to FLT3. This innovate anti-FLT3 provides immediate and lasting neuropathic pain relief in rodents. Credit: Didier Rognan ... […]
via Google News and Bing News